H. Ohori

发表

Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof.

H. Shibata, C. Ishioka, N. Kanoh, 2010, Bioorganic & medicinal chemistry.

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

C. Ishioka, H. Shimodaira, S. Morita, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

S. Kato, C. Ishioka, Takao Suzuki, 2012, Oncology.

Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers

Kazunori Otsuka, H. Shibata, C. Ishioka, 2021, Cancer Chemotherapy and Pharmacology.

KSRP/FUBP2 Is a Binding Protein of GO-Y086, a Cytotoxic Curcumin Analogue.

H. Shibata, C. Ishioka, N. Chiba, 2010, ACS medicinal chemistry letters.

Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03)

S. Iwase, K. Ariyoshi, H. Oshio, 2019, Supportive Care in Cancer.

Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer

H. Shibata, C. Ishioka, Y. Kakudo, 2006, Molecular Cancer Therapeutics.

Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo

H. Shibata, C. Ishioka, H. Nanjo, 2011, BMC pharmacology.

RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer

Masato Nakamura, M. Takeuchi, W. Ichikawa, 2020 .

Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma.

H. Shibata, C. Ishioka, Y. Iwabuchi, 2011, Anticancer research.

Syntheses of naturally occurring cytotoxic [7.7]paracyclophanes, (-)-cylindrocyclophane A and its enantiomer, and implications for biological activity.

H. Shibata, M. Shibuya, N. Kanoh, 2009, Organic & biomolecular chemistry.

Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.

C. Ishioka, Masanobu Takahashi, H. Shirota, 2018, The Tohoku journal of experimental medicine.

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer

C. Ishioka, Masato Nakamura, S. Morita, 2021, Cancer science.

Curcumin analog GO‐Y030 is a novel inhibitor of IKKβ that suppresses NF‐κB signaling and induces apoptosis

H. Shibata, C. Ishioka, Y. Iwabuchi, 2011, Cancer science.

Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo

T. Noda, H. Shibata, C. Ishioka, 2009, Cancer science.

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

C. Ishioka, H. Shimodaira, Takahiro Mori, 2017, PloS one.

Real‐world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6‐NTRK3 positive metastatic salivary secretory carcinoma: A case series

T. Yokota, H. Ohori, M. Doi, 2023, Head & neck.

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.

E. Oki, K. Tsuchihara, K. Muro, 2023, JAMA.

A modified MethyLight assay predicts the clinical outcomes of anti‐epidermal growth factor receptor treatment in metastatic colorectal cancer

C. Ishioka, K. Amagai, T. Okada, 2021, Cancer science.

The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).

Masato Nakamura, M. Takeuchi, Tatsuro Yamaguchi, 2022, Journal of Clinical Oncology.

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.

R. Yamashita, E. Oki, A. Ochiai, 2023, Journal of Clinical Oncology.

Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO.

Masato Nakamura, M. Takeuchi, Tatsuro Yamaguchi, 2023, Journal of Clinical Oncology.

[Complete resection of liver metastases of colorectal cancer after high efficacy bevacizumab, S-1, and CPT -11 combination chemotherapy].

Toru Takahashi, H. Ohori, H. Imai, 2015, Gan to kagaku ryoho. Cancer & chemotherapy.

The Role of Chemotherapy in Brain Metastases( Current Management of Brain Metastasis)

C. Ishioka, H. Ohori, Shin Takahashi, 2007 .

Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.

S. Kato, C. Ishioka, H. Shimodaira, 2018, The Tohoku journal of experimental medicine.

Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial

C. Ishioka, H. Shimodaira, Takuhiro Yamaguchi, 2022, AntiCancer Research.

Multiple cavitary lung lesions from colorectal cancer responding to chemotherapy

Seiichi Kobayashi, M. Yanai, H. Ohori, 2023, Respiratory medicine case reports.

Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer

H. Shibata, C. Ishioka, Y. Kakudo, 2006, Molecular Cancer Therapeutics.

Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof.

H. Shibata, C. Ishioka, N. Kanoh, 2010, Bioorganic & medicinal chemistry.

Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.

R. Yamashita, E. Oki, K. Tsuchihara, 2023, Journal of Clinical Oncology.